000131719 001__ 131719
000131719 005__ 20240229105009.0
000131719 0247_ $$2doi$$a10.1016/j.gie.2017.04.005
000131719 0247_ $$2pmid$$apmid:28431951
000131719 0247_ $$2ISSN$$a0016-5107
000131719 0247_ $$2ISSN$$a1097-6779
000131719 0247_ $$2altmetric$$aaltmetric:19789309
000131719 037__ $$aDKFZ-2018-00025
000131719 041__ $$aeng
000131719 082__ $$a610
000131719 1001_ $$0P:(DE-HGF)0$$aChen, Chen$$b0$$eFirst author
000131719 245__ $$aPublic health impact of colonoscopy use on colorectal cancer mortality in Germany and the United States.
000131719 260__ $$aNew York, NY$$bElsevier$$c2018
000131719 3367_ $$2DRIVER$$aarticle
000131719 3367_ $$2DataCite$$aOutput Types/Journal article
000131719 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659605401_16656
000131719 3367_ $$2BibTeX$$aARTICLE
000131719 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000131719 3367_ $$00$$2EndNote$$aJournal Article
000131719 520__ $$aColonoscopy has been demonstrated to be effective in reducing colorectal cancer (CRC) incidence and mortality and has been widely used for primary CRC screening in Germany and the United States. We performed a population-based analysis to evaluate and compare the public health impact of recent colonoscopy use on CRC deaths among adults aged 55 to 79 years in Germany and the United States from 2008 to 2011.The epidemiologic metrics of attributable fraction and prevented fraction as well as the impact numbers were calculated using colonoscopy utilization data from nationally representative health surveys, relative risk estimates from medical literature, and CRC death registry data.Overall, 36.6% (95% credible interval [CrI], 27.3%-45.5%) of CRC deaths in Germany were estimated to be attributable to nonuse of colonoscopy, compared with the U.S. estimates of 38.2% (95% CrI, 28.6%-47.1%) and 33.6% (95% CrI, 24.8%-42.2%) for years 2008 to 2009 and 2010 to 2011, respectively. The proportion of CRC deaths theoretically prevented by colonoscopy use within 10 years was 30.7% (95% CrI, 24.8%-35.7%) in Germany, whereas in the United States this proportion ranged from 29.0% (95% CrI, 23.4%-33.6%) for 2008 to 2009 to 33.9% (95% CrI, 27.4%-39.2%) for 2010 to 2011.Recent colonoscopy use is likely to have prevented a considerable fraction of CRC mortality in both countries, and more deaths could be avoided by increasing colonoscopy use in the target population. Attributable and prevented fraction can provide valuable information on the public health impact of colonoscopy use and guide policymaking.
000131719 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000131719 588__ $$aDataset connected to CrossRef, PubMed,
000131719 7001_ $$0P:(DE-He78)908880209a64ea539ae8dc5fdb7e0a91$$aStock, Christian$$b1$$udkfz
000131719 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b2$$udkfz
000131719 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000131719 773__ $$0PERI:(DE-600)2006253-9$$a10.1016/j.gie.2017.04.005$$gVol. 87, no. 1, p. 213 - 221.e2$$n1$$p213 - 221.e2$$tGastrointestinal endoscopy$$v87$$x0016-5107$$y2018
000131719 909CO $$ooai:inrepo02.dkfz.de:131719$$pVDB
000131719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000131719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908880209a64ea539ae8dc5fdb7e0a91$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000131719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000131719 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000131719 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000131719 9141_ $$y2018
000131719 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000131719 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bGASTROINTEST ENDOSC : 2015
000131719 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000131719 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000131719 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000131719 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000131719 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000131719 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000131719 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000131719 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bGASTROINTEST ENDOSC : 2015
000131719 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000131719 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000131719 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000131719 980__ $$ajournal
000131719 980__ $$aVDB
000131719 980__ $$aI:(DE-He78)C070-20160331
000131719 980__ $$aI:(DE-He78)G110-20160331
000131719 980__ $$aI:(DE-He78)L101-20160331
000131719 980__ $$aUNRESTRICTED